nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Cytarabine—lymphatic system cancer	0.212	0.318	CbGbCtD
Fosamprenavir—CYP3A4—Teniposide—lymphatic system cancer	0.209	0.313	CbGbCtD
Fosamprenavir—CYP3A4—Mitoxantrone—lymphatic system cancer	0.146	0.219	CbGbCtD
Fosamprenavir—CYP3A4—Vincristine—lymphatic system cancer	0.101	0.151	CbGbCtD
Fosamprenavir—Opportunistic infection—Fludarabine—lymphatic system cancer	0.0159	0.0478	CcSEcCtD
Fosamprenavir—Reaction gastrointestinal—Methotrexate—lymphatic system cancer	0.00567	0.0171	CcSEcCtD
Fosamprenavir—Osteonecrosis—Methotrexate—lymphatic system cancer	0.00508	0.0153	CcSEcCtD
Fosamprenavir—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.00498	0.015	CcSEcCtD
Fosamprenavir—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.00495	0.0149	CcSEcCtD
Fosamprenavir—Opportunistic infection—Methotrexate—lymphatic system cancer	0.0047	0.0142	CcSEcCtD
Fosamprenavir—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00468	0.0141	CcSEcCtD
Fosamprenavir—Neutropenia—Teniposide—lymphatic system cancer	0.00426	0.0129	CcSEcCtD
Fosamprenavir—Neutropenia—Fludarabine—lymphatic system cancer	0.00375	0.0113	CcSEcCtD
Fosamprenavir—Haemoglobin—Teniposide—lymphatic system cancer	0.00367	0.0111	CcSEcCtD
Fosamprenavir—Haemorrhage—Teniposide—lymphatic system cancer	0.00365	0.011	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00364	0.011	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00362	0.0109	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00354	0.0107	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00352	0.0106	CcSEcCtD
Fosamprenavir—Myocardial infarction—Fludarabine—lymphatic system cancer	0.0035	0.0106	CcSEcCtD
Fosamprenavir—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00342	0.0103	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00341	0.0103	CcSEcCtD
Fosamprenavir—Anorexia—Mechlorethamine—lymphatic system cancer	0.00335	0.0101	CcSEcCtD
Fosamprenavir—Haemoglobin—Fludarabine—lymphatic system cancer	0.00322	0.00972	CcSEcCtD
Fosamprenavir—Haemorrhage—Fludarabine—lymphatic system cancer	0.00321	0.00967	CcSEcCtD
Fosamprenavir—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00306	0.00922	CcSEcCtD
Fosamprenavir—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00303	0.00915	CcSEcCtD
Fosamprenavir—Malnutrition—Fludarabine—lymphatic system cancer	0.00279	0.00842	CcSEcCtD
Fosamprenavir—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00259	0.00782	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00258	0.00779	CcSEcCtD
Fosamprenavir—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00257	0.00774	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00255	0.00769	CcSEcCtD
Fosamprenavir—Pruritus—Mechlorethamine—lymphatic system cancer	0.00249	0.0075	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00248	0.00749	CcSEcCtD
Fosamprenavir—Anorexia—Teniposide—lymphatic system cancer	0.00247	0.00745	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00243	0.00734	CcSEcCtD
Fosamprenavir—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00241	0.00726	CcSEcCtD
Fosamprenavir—Neutropenia—Carmustine—lymphatic system cancer	0.0024	0.00723	CcSEcCtD
Fosamprenavir—Myalgia—Fludarabine—lymphatic system cancer	0.00238	0.00717	CcSEcCtD
Fosamprenavir—Haemoglobin—Bleomycin—lymphatic system cancer	0.00236	0.00713	CcSEcCtD
Fosamprenavir—Haemorrhage—Bleomycin—lymphatic system cancer	0.00235	0.00709	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00231	0.00698	CcSEcCtD
Fosamprenavir—Neutropenia—Vincristine—lymphatic system cancer	0.00229	0.0069	CcSEcCtD
Fosamprenavir—Decreased appetite—Teniposide—lymphatic system cancer	0.00225	0.0068	CcSEcCtD
Fosamprenavir—Vomiting—Mechlorethamine—lymphatic system cancer	0.00224	0.00674	CcSEcCtD
Fosamprenavir—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00224	0.00674	CcSEcCtD
Fosamprenavir—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00223	0.00672	CcSEcCtD
Fosamprenavir—Rash—Mechlorethamine—lymphatic system cancer	0.00222	0.00669	CcSEcCtD
Fosamprenavir—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00222	0.00668	CcSEcCtD
Fosamprenavir—Anorexia—Fludarabine—lymphatic system cancer	0.00217	0.00655	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00215	0.00649	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00215	0.00649	CcSEcCtD
Fosamprenavir—Myocardial infarction—Vincristine—lymphatic system cancer	0.00214	0.00645	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00212	0.00639	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0021	0.00632	CcSEcCtD
Fosamprenavir—Nausea—Mechlorethamine—lymphatic system cancer	0.00209	0.0063	CcSEcCtD
Fosamprenavir—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00208	0.00629	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00208	0.00626	CcSEcCtD
Fosamprenavir—Haemoglobin—Carmustine—lymphatic system cancer	0.00206	0.00622	CcSEcCtD
Fosamprenavir—Haemorrhage—Carmustine—lymphatic system cancer	0.00205	0.00619	CcSEcCtD
Fosamprenavir—Abdominal pain—Teniposide—lymphatic system cancer	0.00205	0.00618	CcSEcCtD
Fosamprenavir—Body temperature increased—Teniposide—lymphatic system cancer	0.00205	0.00618	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00202	0.00608	CcSEcCtD
Fosamprenavir—Decreased appetite—Fludarabine—lymphatic system cancer	0.00198	0.00597	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00197	0.00593	CcSEcCtD
Fosamprenavir—Fatigue—Fludarabine—lymphatic system cancer	0.00196	0.00593	CcSEcCtD
Fosamprenavir—Inflammation—Methotrexate—lymphatic system cancer	0.00195	0.00589	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00194	0.00584	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00193	0.00581	CcSEcCtD
Fosamprenavir—Urethral disorder—Vincristine—lymphatic system cancer	0.00192	0.00579	CcSEcCtD
Fosamprenavir—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00192	0.00579	CcSEcCtD
Fosamprenavir—Hypersensitivity—Teniposide—lymphatic system cancer	0.00191	0.00576	CcSEcCtD
Fosamprenavir—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00191	0.00576	CcSEcCtD
Fosamprenavir—Asthenia—Teniposide—lymphatic system cancer	0.00186	0.00561	CcSEcCtD
Fosamprenavir—Pruritus—Teniposide—lymphatic system cancer	0.00183	0.00553	CcSEcCtD
Fosamprenavir—Cardiac disorder—Vincristine—lymphatic system cancer	0.00182	0.00549	CcSEcCtD
Fosamprenavir—Body temperature increased—Fludarabine—lymphatic system cancer	0.0018	0.00543	CcSEcCtD
Fosamprenavir—Malnutrition—Carmustine—lymphatic system cancer	0.00179	0.00539	CcSEcCtD
Fosamprenavir—Diarrhoea—Teniposide—lymphatic system cancer	0.00177	0.00535	CcSEcCtD
Fosamprenavir—Myalgia—Bleomycin—lymphatic system cancer	0.00174	0.00526	CcSEcCtD
Fosamprenavir—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00168	0.00506	CcSEcCtD
Fosamprenavir—Vomiting—Teniposide—lymphatic system cancer	0.00165	0.00497	CcSEcCtD
Fosamprenavir—Asthenia—Fludarabine—lymphatic system cancer	0.00164	0.00493	CcSEcCtD
Fosamprenavir—Rash—Teniposide—lymphatic system cancer	0.00164	0.00493	CcSEcCtD
Fosamprenavir—Dermatitis—Teniposide—lymphatic system cancer	0.00163	0.00493	CcSEcCtD
Fosamprenavir—Headache—Teniposide—lymphatic system cancer	0.00162	0.0049	CcSEcCtD
Fosamprenavir—Pruritus—Fludarabine—lymphatic system cancer	0.00161	0.00486	CcSEcCtD
Fosamprenavir—Anorexia—Bleomycin—lymphatic system cancer	0.00159	0.0048	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00158	0.00477	CcSEcCtD
Fosamprenavir—Diarrhoea—Fludarabine—lymphatic system cancer	0.00156	0.0047	CcSEcCtD
Fosamprenavir—Nausea—Teniposide—lymphatic system cancer	0.00154	0.00465	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00152	0.00459	CcSEcCtD
Fosamprenavir—Myalgia—Carmustine—lymphatic system cancer	0.00152	0.00459	CcSEcCtD
Fosamprenavir—Decreased appetite—Bleomycin—lymphatic system cancer	0.00145	0.00438	CcSEcCtD
Fosamprenavir—Myalgia—Vincristine—lymphatic system cancer	0.00145	0.00438	CcSEcCtD
Fosamprenavir—Vomiting—Fludarabine—lymphatic system cancer	0.00145	0.00437	CcSEcCtD
Fosamprenavir—Rash—Fludarabine—lymphatic system cancer	0.00144	0.00433	CcSEcCtD
Fosamprenavir—Dermatitis—Fludarabine—lymphatic system cancer	0.00144	0.00433	CcSEcCtD
Fosamprenavir—Headache—Fludarabine—lymphatic system cancer	0.00143	0.00431	CcSEcCtD
Fosamprenavir—Myalgia—Mitoxantrone—lymphatic system cancer	0.00141	0.00427	CcSEcCtD
Fosamprenavir—Anorexia—Carmustine—lymphatic system cancer	0.00139	0.00419	CcSEcCtD
Fosamprenavir—Nervous system disorder—Vincristine—lymphatic system cancer	0.00137	0.00412	CcSEcCtD
Fosamprenavir—Nausea—Fludarabine—lymphatic system cancer	0.00135	0.00408	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00133	0.00401	CcSEcCtD
Fosamprenavir—Anorexia—Vincristine—lymphatic system cancer	0.00133	0.004	CcSEcCtD
Fosamprenavir—Body temperature increased—Bleomycin—lymphatic system cancer	0.00132	0.00398	CcSEcCtD
Fosamprenavir—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00132	0.00397	CcSEcCtD
Fosamprenavir—Anorexia—Mitoxantrone—lymphatic system cancer	0.00129	0.0039	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00127	0.00383	CcSEcCtD
Fosamprenavir—Decreased appetite—Carmustine—lymphatic system cancer	0.00127	0.00382	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00126	0.0038	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00124	0.00373	CcSEcCtD
Fosamprenavir—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00123	0.00371	CcSEcCtD
Fosamprenavir—Decreased appetite—Vincristine—lymphatic system cancer	0.00121	0.00365	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0012	0.00363	CcSEcCtD
Fosamprenavir—Fatigue—Vincristine—lymphatic system cancer	0.0012	0.00362	CcSEcCtD
Fosamprenavir—Asthenia—Bleomycin—lymphatic system cancer	0.0012	0.00362	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00119	0.0036	CcSEcCtD
Fosamprenavir—Pruritus—Bleomycin—lymphatic system cancer	0.00118	0.00357	CcSEcCtD
Fosamprenavir—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00118	0.00355	CcSEcCtD
Fosamprenavir—Fatigue—Mitoxantrone—lymphatic system cancer	0.00117	0.00353	CcSEcCtD
Fosamprenavir—Abdominal pain—Carmustine—lymphatic system cancer	0.00115	0.00348	CcSEcCtD
Fosamprenavir—Body temperature increased—Carmustine—lymphatic system cancer	0.00115	0.00348	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00114	0.00343	CcSEcCtD
Fosamprenavir—Neutropenia—Methotrexate—lymphatic system cancer	0.00111	0.00335	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00111	0.00334	CcSEcCtD
Fosamprenavir—Abdominal pain—Vincristine—lymphatic system cancer	0.0011	0.00332	CcSEcCtD
Fosamprenavir—Body temperature increased—Vincristine—lymphatic system cancer	0.0011	0.00332	CcSEcCtD
Fosamprenavir—Hypersensitivity—Carmustine—lymphatic system cancer	0.00107	0.00324	CcSEcCtD
Fosamprenavir—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00107	0.00323	CcSEcCtD
Fosamprenavir—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00107	0.00323	CcSEcCtD
Fosamprenavir—Vomiting—Bleomycin—lymphatic system cancer	0.00106	0.0032	CcSEcCtD
Fosamprenavir—Rash—Bleomycin—lymphatic system cancer	0.00105	0.00318	CcSEcCtD
Fosamprenavir—Dermatitis—Bleomycin—lymphatic system cancer	0.00105	0.00317	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00105	0.00317	CcSEcCtD
Fosamprenavir—Asthenia—Carmustine—lymphatic system cancer	0.00105	0.00316	CcSEcCtD
Fosamprenavir—Hypersensitivity—Vincristine—lymphatic system cancer	0.00103	0.00309	CcSEcCtD
Fosamprenavir—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000999	0.00301	CcSEcCtD
Fosamprenavir—Asthenia—Vincristine—lymphatic system cancer	0.000999	0.00301	CcSEcCtD
Fosamprenavir—Diarrhoea—Carmustine—lymphatic system cancer	0.000998	0.00301	CcSEcCtD
Fosamprenavir—Nausea—Bleomycin—lymphatic system cancer	0.000993	0.00299	CcSEcCtD
Fosamprenavir—Asthenia—Mitoxantrone—lymphatic system cancer	0.000973	0.00293	CcSEcCtD
Fosamprenavir—Dizziness—Carmustine—lymphatic system cancer	0.000965	0.00291	CcSEcCtD
Fosamprenavir—Haemoglobin—Methotrexate—lymphatic system cancer	0.000956	0.00288	CcSEcCtD
Fosamprenavir—Diarrhoea—Vincristine—lymphatic system cancer	0.000953	0.00287	CcSEcCtD
Fosamprenavir—Haemorrhage—Methotrexate—lymphatic system cancer	0.000951	0.00287	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000939	0.00283	CcSEcCtD
Fosamprenavir—Urethral disorder—Methotrexate—lymphatic system cancer	0.000932	0.00281	CcSEcCtD
Fosamprenavir—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000928	0.0028	CcSEcCtD
Fosamprenavir—Vomiting—Carmustine—lymphatic system cancer	0.000927	0.0028	CcSEcCtD
Fosamprenavir—Dizziness—Vincristine—lymphatic system cancer	0.000921	0.00278	CcSEcCtD
Fosamprenavir—Rash—Carmustine—lymphatic system cancer	0.00092	0.00277	CcSEcCtD
Fosamprenavir—Dermatitis—Carmustine—lymphatic system cancer	0.000919	0.00277	CcSEcCtD
Fosamprenavir—Headache—Carmustine—lymphatic system cancer	0.000914	0.00276	CcSEcCtD
Fosamprenavir—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000899	0.00271	CcSEcCtD
Fosamprenavir—Vomiting—Vincristine—lymphatic system cancer	0.000885	0.00267	CcSEcCtD
Fosamprenavir—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000883	0.00266	CcSEcCtD
Fosamprenavir—Rash—Vincristine—lymphatic system cancer	0.000878	0.00265	CcSEcCtD
Fosamprenavir—Dermatitis—Vincristine—lymphatic system cancer	0.000877	0.00265	CcSEcCtD
Fosamprenavir—Headache—Vincristine—lymphatic system cancer	0.000872	0.00263	CcSEcCtD
Fosamprenavir—Nausea—Carmustine—lymphatic system cancer	0.000866	0.00261	CcSEcCtD
Fosamprenavir—Vomiting—Mitoxantrone—lymphatic system cancer	0.000862	0.0026	CcSEcCtD
Fosamprenavir—Immune system disorder—Methotrexate—lymphatic system cancer	0.000859	0.00259	CcSEcCtD
Fosamprenavir—Rash—Mitoxantrone—lymphatic system cancer	0.000855	0.00258	CcSEcCtD
Fosamprenavir—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000854	0.00258	CcSEcCtD
Fosamprenavir—Headache—Mitoxantrone—lymphatic system cancer	0.00085	0.00256	CcSEcCtD
Fosamprenavir—Malnutrition—Methotrexate—lymphatic system cancer	0.000828	0.0025	CcSEcCtD
Fosamprenavir—Nausea—Vincristine—lymphatic system cancer	0.000827	0.00249	CcSEcCtD
Fosamprenavir—Nausea—Mitoxantrone—lymphatic system cancer	0.000805	0.00243	CcSEcCtD
Fosamprenavir—Myalgia—Methotrexate—lymphatic system cancer	0.000705	0.00213	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0007	0.00211	CcSEcCtD
Fosamprenavir—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000663	0.002	CcSEcCtD
Fosamprenavir—Skin disorder—Methotrexate—lymphatic system cancer	0.000656	0.00198	CcSEcCtD
Fosamprenavir—Anorexia—Methotrexate—lymphatic system cancer	0.000644	0.00194	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000616	0.00186	CcSEcCtD
Fosamprenavir—Decreased appetite—Methotrexate—lymphatic system cancer	0.000587	0.00177	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000583	0.00176	CcSEcCtD
Fosamprenavir—Fatigue—Methotrexate—lymphatic system cancer	0.000583	0.00176	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000552	0.00167	CcSEcCtD
Fosamprenavir—Abdominal pain—Methotrexate—lymphatic system cancer	0.000534	0.00161	CcSEcCtD
Fosamprenavir—Body temperature increased—Methotrexate—lymphatic system cancer	0.000534	0.00161	CcSEcCtD
Fosamprenavir—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000498	0.0015	CcSEcCtD
Fosamprenavir—Asthenia—Methotrexate—lymphatic system cancer	0.000485	0.00146	CcSEcCtD
Fosamprenavir—Pruritus—Methotrexate—lymphatic system cancer	0.000478	0.00144	CcSEcCtD
Fosamprenavir—Diarrhoea—Methotrexate—lymphatic system cancer	0.000462	0.00139	CcSEcCtD
Fosamprenavir—Dizziness—Methotrexate—lymphatic system cancer	0.000447	0.00135	CcSEcCtD
Fosamprenavir—Vomiting—Methotrexate—lymphatic system cancer	0.00043	0.0013	CcSEcCtD
Fosamprenavir—Rash—Methotrexate—lymphatic system cancer	0.000426	0.00128	CcSEcCtD
Fosamprenavir—Dermatitis—Methotrexate—lymphatic system cancer	0.000426	0.00128	CcSEcCtD
Fosamprenavir—Headache—Methotrexate—lymphatic system cancer	0.000423	0.00128	CcSEcCtD
Fosamprenavir—Nausea—Methotrexate—lymphatic system cancer	0.000401	0.00121	CcSEcCtD
